Please join Ocular Therapeutix™ for its 2025 Investor Day featuring presentations from Ocular’s senior leadership and roundtable discussions with global retina Key Opinion Leaders (KOLs), followed by a live Q&A session. In-person attendees are invited to join Ocular’s leadership team for a networking reception to conclude the event.

The global retina KOLs participating in Ocular’s Investor Day include:

• Dr. Arshad M. Khanani MD, MA, FASRS: Managing Partner, Director of Clinical Research and Director of Fellowship, Sierra Eye Associates, and Clinical Professor, University of Nevada, Reno School of Medicine
• Professor Adnan Tufail, MBBS, MD, FRCOphth: Professor, The Institute of Ophthalmology, University College London, England and Consultant Ophthalmic Surgeon, Moorfields Eye Hospital NHS Foundation Trust
• Dr. Eleonora Lad, MD, PhD: Vice Chair of Ophthalmology Clinical Research and Professor of Ophthalmology, Duke University Medical Center
• Dr. Patricio G. Schlottmann, MD: Director of the Research Department at the Charles Ophthalmic Center and Ophthalmology Department Director at Organización Médica de Investigación in Buenos Aires, Argentina

Presentations from Company leadership and KOL discussions will focus on providing an overview of the complementary SOL trials and how they may support a differentiated superiority label for AXPAXLI in wet age-related macular degeneration (wet AMD); details on the planned SOL extension study; the Company’s clinical strategy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME), and a review of the global commercial opportunity for AXPAXLI across retinal indications.